remuneration of doctors in the service, and the special features distinguishing OH work in hospitals from that in industry. Had time permitted, there would certainly have been much more. The size of the audience and the quality of the papers and discussion showed that this sector of occupational medicine, neglected for so long but now its biggest growth point, is well on the way to maturity.
FRANK H TYRER
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Rieferences DeI to(Healtha.d Sci Secirky (1982) (1983) Occupational Hazards in Hospitals. Euro Reports and Studies 80. WHO, Copenhagen Recent advances in the immunology and molecular biology of the heart'
The ways in which new techniques in immunology and molecular biology are being used to study heart disease was discussed at a meeting organized by the Section of Clinical Immunology & Allergy on 15 October 1984 under the aegis of the British Heart Foundation, which supported the research of 7 of the speakers. Work was presented on clinical and experimental uses for monoclonal antibodies to heart muscle contractile proteins, the nature of the cells which infiltrte cardiac transplants, the iunology of nfmatory heart disease and dilated cardiomyopathy, and the actions of leukotrienes on the heart.
Monoclonal andpolyclonal antibodies to cardiac contractileproteins The use of isotype-specific antibodies to components of the tropomyosin-troponin complex, for measuring serun levels following cardiac injury, 'Report of meeting of the Section of Clinical Immunology & Allergy, 15 October 1984 . Accepted 3 June 1985 was discussed by Dr Peter Cummins, University of Birmingham. Several contractile proteins, inchlding cardiac myosin, actin, troponin-I and troponin-T exist in isotype forms which are located exclusively or preferentially in the heart. Others, such as tropomyosin and troponin-C have common isotypes which are also present in skeletal muscle. Cardiac myosin, the most prevalent contractile protein in the cardiac myofibril, exists in several forms, with two heavy chain and four light chain subunits, each of which has several isotypes. These may be variably expressed in differing amounts in each part of the heart in man (Mercadier et al 1983) , particularly in the atria (Cummins 1982) . Expression is altered during ontogeny, and marked species differences have been found. For example, in rodents there is little regional variation in myosin isotype expression. The amounts of each cardiac myosin isotype have also been shown to change during pressure overload, exercise, and in a number of diseases, including tetralogy of Fallot (Cummins & Auckland 1984) and coxsackie myocarditis in mice 0141-0768/85/090777-05/$02.O00/ (Matsumori et al. 1984) . For a review see Cummins (1983) .
The cardiac isotype of actin differs from the skeletal muscle isotype in only a few of its nearly 400 amino acid residues, and is not an ideal candidate as a cardiac-specific isotype. Most attention has focused on myosin and the proteins of the tropomyosin-troponin complex. Sensitive assays have been developed using polyclonal and monoclonal antibodies to several of the contractile protein isotypes, including cardiac myosin heavy and light chains, cardiac/skeletal tropomyosin and cardiac troponin-I. Following myocardial infarction, serum levels of tropomyosin increased, correlating with the established methods for assessing the amount of myocardial damage, such as serum levels of creatine kinase MB (Cummins et al. 1981) . In a group of patients with myocardial infarction, serum tropomyosin concentrations followed a biphasic pattern, with a secondary peak at 55 hours and levels persisting for up to 12 days, and there were no false-positive or negative results. This, therefore, is a useful late test for cardiac injury, providing there is no associated skeletal muscle damage (Cummins et al. 1981) .
The cardiac form of troponin-I differs from the slow and fast skeletal isotypes in about 40% of its amino acid residues, with an additional unique 26 residue C-terminal peptide. The cardiac isotype is uniformly distributed in the heart (Humphreys & Cummins 1984) . For these reasons, it has advantages as a measure of cardiac damage, being a totally cardiac-specific marker. Serum levels rose within 3-5 hours of acute myocardial infarction, from 10 ng/ml to over 150 ng/ml depending on the infarct size (Cummins & Auckland 1983). A biphasic release profile occurred, with elevated troponin-I levels for up to 7-8 days postinfarction. Studies are currently in progress on the use of labelled troponin-I antibodies for radionuclide imaging of areas of cardiac damage.
A number of antibodies have been raised to skeletal muscle antigens, which are also present in the heart. Some of these now show biochemical heterogeneity of cells within the heart (Gorza et al. 1982) . Dr Gurtej Dhoot, Department of Immunology, The Medical School, Birmingham, discussed this aspect, and described the properties of two monoclonal antibodies which she has used for this purpose. One monoclonal antibody (92B21), which bound a 100 kd slow myofibrillar protein in skeletal muscle (Dhoot 1985) , also recognized a component in about 70% of human and rabbit atrial muscle cells, and all ventricular cells. It bound to cultured cardiac cells, but not to cultured skeletal muscle cells. Another antibody (83B24), which was specific for the slow skeletal muscle C-protein in the A band (Dhoot et al. 1985) , stained only a proportion of the atrial cells which might be a part of the conducting system. This antibody did not react with ventricular tissue in adults. The significance of a small proportion of atrial cells containing slow skeletal muscle like C-protein is not clear.
One important application of monoclonal antibodies is to define sites of myocardial damage using radionuclide imaging. Dr Jocelyn Dow, Department of Biochemistry, Glasgow, discussed the potential value of antibodies to cardiac myosin and mitochondrial membrane antigens, which would only become accessible to monoclonal antibodies when heart muscle cells had become irreversibly damaged. She described an IgM antibody to rat myosin heavy chain of the cross-bridge (heavy meromyosin) which may be readily accessible to antibodies in damaged muscle cells. Fluorescent-labelled antibody entered and was retained in calcium-tolerant rat heart cells in vitro only after they had been damaged irreversibly by hypoxia (Dow et al. 1981a, b) . Work is now in progress, using 125-I-labelled antibody, to image sites of experimental ischaemic cardiac injury, and similar studies are being done with mouse IgGI and IgG2a antibodies to cardiac mitochondrial antigens.
For several years, a group at Harvard Medical School, Boston, has been pioneering the use of monoclonal antibodies to study human cardiac diseases. This was described by Professor Edgar Haber. Because the MB isozyme of creatine kinase (one of the most widely used serum assays for myocardial damage) is not confined to the heart, antibodies were prepared to cardiac myosin, as this would provide a more specific assay for the release of cardiac constituents into the blood (Katus et al. 1982) . A double antibody technique was developed to provide complete specificity for cardiac myosin light chains. The assay was used to measure myosin levels in the circulation after myocardial infarction in animals (Khaw et al. 1978b (Khaw et al. , 1979 , and man (Katus et al. 1985) . Raised serum levels of cardiac myosin light chains have recently been noted in a subgroup of patients with dilated cardiomyopathy and inflammatory cells in the cardiac biopsy, but normal serum creatine kinase MB levels.
As myosin is not expressed on cell surfaces, and antibodies cannot enter intact heart cells, it was expected that these antibodies would only bind to heart cells which were extruding their contents. This was confirmed when scanning electronmicrographs were made with antimyosin antibody-coated 1u polystyrene beads mixed with damaged and viable mouse heart cells in vitro. The beads were clustered around membrane defects in the damaged cells. When fluorescent antibodycoated particles were used, damaged cells with attached fluorescent beads were separated from non-fluorescent intact heart cells in a cell sorter. The cells in the fluorescent fractions did not survive in culture, whereas the cells in the nonfluorescent fractions were viable, showing that the labelled antibodies would only bind to irreversibly damaged heart cells (Khaw et al. 1982) .
Intravenous injection of radiolabelled (Fab')2 antibody to cardiac myosin light chains was able to provide high quality gamma-camera scintigraphy pictures of areas of ischaemic cardiac injury in dogs, and pictures were obtained within an hour of coronary artery occlusion (Khaw et al. 1976 (Khaw et al. , 1978a (Khaw et al. , c, 1983 . Uptake was maximal at three hours, and the extent was proportional to the eventual sizes of the infarcts (Frame et al. 1983) .
Then clinical studies were carried out on 24 patients with myocardial infarctions who were followed up for 15 months after intravenous injection of 99"Tc-labelled-Fab monoclonal myosin antibodies. Clear gamma-camera images began to be seen within 18 hours of onset of symptoms. Planar measurements demonstrated a close correlation between the extent of uptake of the label, and (a) ventricular akinesis assessed at ten days and (b) tomographic volumes. The images gave a predictive value of 79%, whereas peak serum creatine kinase MB levels were not predictive. Previously it had been shown that 99mTc pyrophosphate images overestimated the sizes of the infarcts by about 1 5 (Beller et al. 1977) . Uptake of the labelled antibodies did not occur in patients with angina alone. The main problems with the method at present are that inferior infarcts are less well seen than anterior lesions, and it is difficult to label the antibodies with 99mTc. Recently, 111indium-labelled antibodies have been used, and this has overcome some of the technical difficulties, giving higher quality images. It is now proposed to use this method to study the effects of coronary vessel thrombolysis, and angioplasty on ischaemic heart disease.
Inflammatory cells in the heart
Another important use of monoclonal antibodies in the study of cardiovascular disease is in determining the types of cells within the heart in different diseases. Monoclonal antibodies to lymphocyte and macrophage membrane antigens have been used to study the numbers and distribution of these cells within the transplanted heart. This area was discussed by Dr Patricia Chisholm, Chelsea College, who first described the cellular events which occurred in rats given mismatched heart grafts. Radiolabelled syngeneic thoracic duct lymphocytes localized in the rejecting allogeneic grafts to a greater extent than in either syngeneic heart grafts or allogeneic grafts in cyclosporine-treated recipients, and most uptake occurred soon after grafting was carried out (Cox et al. 1984) . Many of the cells within the rejecting hearts had the cytotoxic/suppressor phenotype, and many were also Ia-positive (Chisholm et al. 1985) . In cyclosporine-treated allogeneic heart grafts it was found that only a quarter of the infiltrating cells were T lymphocytes and one-eighth cytotoxic/ suppressor lymphocytes. There were only occasional (Ia-negative) macrophages. This suggests that the beneficial effects ofcyclosporine in cardiac transplantation might be partly related to druginduced inhibition of the uptake of cytotoxic T lymphocytes into the heart. Similar differences were also noted in biopsies from human heart allograft in patients receiving conventional immunosuppressive treatment or cyclosporine (Rose etal. 1984) . Immunology ofdilated cardiomyopathy For over a decade the possiblility has been considered that some chronic heart muscle diseases of man, including dilated cardiomyopathy, might be due to or associated with abnormal immunological responses to heart muscle antigens (Camp et al. 1969) . This topic was discussed by Dr Patricia Lowry, East Birmingham Hospital, Birmingham. She and her colleagues have not been convinced by the results of earlier work which was thought, at the time, to show an association between antiheart antibodies and dilated cardiomyopathy, and more recent studies suggesting that cell-mediated reactions might have a pathogenetic role in this (and other) diseases. Others have noted both depression of cell-mediated immune responses in some patients with dilated cardiomyopathy, as well as increased responses in others (Das et al. 1980 (Das et al. , 1981 . Their own work with samples from 28 patients with dilated cardiomyopathy, 15 with hypertrophic cardiomyopathy and 16 with ischaemic heart disease, has failed to show a higher incidence of antibodies in patients with dilated cardiomyopathy than controls, and patients' heart muscle cells did not have increased amounts of immunoglobulins on their surface (Trueman et al. 1981 , Lowry et al. 1983 ). In addition, there were no differences between the groups in their capacity to make skin delayed-hypersensitivity responses, migration inhibitory factor from blood lymphocytes, or lymphocyte blastogenic responses to environmental antigens, or mitogens (Lowry et al. 1985a) . However a small number of patients with a rapidly progressive form of dilated cardiomyopathy, with a short history, demonstrated leukcocyte migration inhibition to heart antigens, suggesting that these patients may have become sensitized to heart muscle antigens (Lowry et al. 1985b ).
Inflammation and cardiac injury
Several forms of heart muscle disease are associated with large numbers of inflammatory cells in the myocardium. The range of diseases with this characteristic were reviewed by Dr Christopher Spry, Hammersmith Hospital, London. Patients with a marked eosinophilia, especially the idiopathic hypereosinophilic syndrome (Spry 1982) , are particularly likely to develop myocardial damage leading to eosinophilic endomyocardial disease (Davies et ol. 1983a) . Work on the pathogenesis of this disease has shown that the eosinophil basic proteins, which have an important role in defence against some parastites, are probably the cause of the cardiac damage (Olsen & Spry 1985) . Eosinophils contain several highly cytotoxic basic proteins, which can injure isolated rat cardiac myocytes (Tai et al. 1982) . Monoclonal antibodies have been made to each of them, including some of the secreted forms of these proteins (Tai et al. 1984b) , and they are now being used to assess the possible involvement of granulocyte constituents in heart muscle diseases (Tai et al.1984a ). A recent collaborative study has demonstrated the presence of two basic proteins (eosinophil major basic protein and eosinophil cationic protein) in the areas of acute necrosis, and on the surface of adjacent myocardial cells in 18 patients with eosinophilic endomyocardial disease (Tai et al., in preparation) . There are a number of reasons to support the suggestion that tropical endomyocardial fibrosis has the same pathogenesis (Davies et al. 1983b ).
Leukotrienes and the heart There has been growing awareness of the importance of arachidonic acid metabolites, including the leukotrienes (Samuelsson 1983) , in causing coronary vasoconstriction in man. Research in this area was reviewed by Professor Priscilla Piper, Royal College of Surgeons, London. So far, most of the work has been done in experimental animals. This has shown that there are species differences, and variations in the sensitivity of the vasculature in different organs, to the effects of these mediators (see Piper 1983) , so the findings in animals cannot be easily applied to human disease. However, there is no doubt of the potent effects of leukotrienes on the coronary blood supply in several species. In the Langendorff preparation of guinea-pig hearts, coronary blood flow was reduced by infusion of leukotrienes C4 and D4, and they had a negative ionotropic effect (Michelassi et a. 1982) . Similarly in the intact pig, LTD4 induced coronary artery vasoconstriction, which could be longlasting when higher concentrations were used (McLeod et al. 1984) . As these effects could not be inhibited by indomethacin, they appeared to be independent of the cyclo-oxygenase pathway of arachidonic acid metabolism (Greenwald et al. 1984) . The vasospastic properties of the leukotrienes were less marked in anaesthetized dogs (Woodman & Dusting 1983) . Leukotriene C4, which is one of the cysteinyl-containing leukotrienes, may be formed by the 5-lipoxygenase system within the adventitia and intima of coronary vessels as a result of local damage . Leukotriene B4 can be formed in each part of the arterial wall, where it may act as a potent inducer of neutrophil accumulation and secretion (Ford-Hutchinson et al. 1980) . There is clearly great potential for these mediators as regulators of human coronary vessel diameter, and diseases affecting the blood supply to the heart.
Conclusions
This meeting brought together several groups who are using new molecular biological, immunological and imaging techniques for studying cardiovascular diseases. The precision of the methods discussed in this meeting has been of particular value in studies which examined small differences between patients and control subjects, such as alterations in serum levels of cardiac-specific contractile proteins. It is this precision, and the finesse which is now available with these methods, which may lead within the next few years to the unravelling of some of the complex processes which lead to myocardial damage in man.
